ScinoPharm Taiwan Ltd (TWSE:1789), a process R&D and API manufacturing service provider to the global pharmaceutical industry, announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for Glatiramer Acetate Injection, a treatment for Multiple Sclerosis (MS).

According to ScinoPharm Taiwan, it is the only pharmaceutical company in Taiwan to achieve this milestone.

The company says that it is actively progressing regulatory submissions and forging collaborations across Europe, Asia, and emerging markets to expand its international presence in the generic drug product market and build on its already strong position on the generic API front.